ライフサイエンスコーパス: heart attack

1 eral inflammation (e.g., infection, surgery, heart attack).

2 de protection against myocardial infarction (heart attacks).

3 e significant declines in community rates of heart attack.

4 to the brain or heart, leading to stroke or heart attack.

5 se fields, including treatment of stroke and heart attack.

6 tes mellitus, glucose, and family history of heart attack.

7 ed as genes implicated in predisposition for heart attack.

8 value reached in the first few minutes of a heart attack.

9 when heart muscle cells die en masse after a heart attack.

10 creased cardiac damage in an animal model of heart attack.

11 % of respondents; of these, 67.8% reported a heart attack.

12 rrent smoking; and no history of diabetes or heart attack.

13 ffer new hope for patients suffering massive heart attacks.

14 ew therapeutic interventions for strokes and heart attacks.

15 farction, one of the most prevalent forms of heart attacks.

16 risk for development of premature, familial heart attacks.

17 ss strenuous PA had little effect on risk of heart attacks.

18 ons that raise LDLRs reduce LDL and diminish heart attacks.

19 life-threatening events, such as strokes and heart attacks.

20 reducing the tissue damage that is caused by heart attacks.

21 ation (36%) rather than heart disease (17%), heart attack (14%), or stroke (5%).

22 g the 3.1% of respondents with self-reported heart attack, 32.8% had claims-identified AMI, 16.5% had

23 sm (54%) and deep-vein thrombosis (44%) than heart attack (88%) and stroke (85%).

24 detect myocyte death are used to diagnose a heart attack (acute myocardial infarction, AMI), there i

25 and PM(2.5)) and to the type of outcome (MI, heart attack, acute coronary syndrome).

26 king group has been convened by the National Heart Attack Alert Program (which is coordinated by the

27 mong participants without self-reported CHD (heart attack and angina pectoris), stroke, peripheral va

28 1.5-5.1) and among those with self-reported heart attack and claims-identified AMI (odds ratio, 2.5;

29 ypertension is a significant risk factor for heart attack and stroke and represents a major public he

30 .g., rofecoxib [Vioxx]) increase the risk of heart attack and stroke and should be avoided in patient

31 drome have a significantly increased risk of heart attack and stroke compared with people with normal

32 Although reports of parental premature heart attack and stroke had high likelihood ratios, thei

33 tion and atherosclerosis, the major cause of heart attack and stroke in humans.

34 s could be associated with the prevention of heart attack and stroke in humans.

35 orapaxar [SCH 530348; MK-5348] in Preventing Heart Attack and Stroke in Participants With Acute Coron

36 sess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary

37 ssess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis

38 ssess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis

39 sess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis

40 Given the recent declines in heart attack and stroke incidence, it is unclear how wom

41 sterone levels are associated with increased heart attack and stroke risk.

42 Unwanted clots lead to heart attack and stroke that result in a large number of

43 gen is a primary step in the pathogenesis of heart attack and stroke, and drugs to block platelet act

44 the small intestine, thus protecting against heart attack and stroke.

45 tored, and underlies many disorders, notably heart attack and stroke.

46 aemia-reperfusion injury in murine models of heart attack and stroke.

47 and volume are independent risk factors for heart attack and stroke.

48 e of death from cardiovascular disease after heart attack and stroke.

49 ises blood pressure, increasing the risk for heart attack and stroke.

50 r safer antiplatelet therapeutics to prevent heart attack and stroke.

51 hat PAD is associated with increased risk of heart attack and stroke; and only 14% were aware that PA

52 n the coronary arteries, which can result in heart attack and sudden death, is a common disease and p

53 d that more strenuous PA reduced the risk of heart attack and that it was necessary to continue PA af

54 c pain--examples include the chest pain of a heart attack and the leg pain of a 30 s sprint--occurs w

55 35 cases indicated that two-thirds had had a heart attack and the remainder had other coronary heart

56 timates, a twofold higher incidence of fatal heart attacks and a 10% higher incidence of cancer than

57 or the importance of PA in the prevention of heart attacks and as a public health recommendation and

58 sis and in arterial thrombosis, which causes heart attacks and other events triggered by abnormal clo

59 vated inappropriately and causes thrombosis, heart attacks and stroke.

60 ature arteriosclerotic disease that leads to heart attacks and strokes at a mean age of 13 years.

61 Plaque disruption, a major cause of heart attacks and strokes, cannot generally be predicted

62 Heart attacks and strokes, leading causes of deaths glob

63 s the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of dea

64 nitiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortalit

65 -dependent arterial thrombosis triggers most heart attacks and strokes.

66 n, is responsible for considerable damage in heart attacks and strokes.

67 s about statin therapy for the prevention of heart attacks and strokes.

68 ues plays a critical role in pathogenesis of heart attacks and strokes.

69 t clots can obstruct blood vessels and cause heart attacks and strokes.

70 ause of most cases of myocardial infarction (heart attack) and of about 80% of strokes, collectively

71 so causes severe tissue damage after stroke, heart attack, and other ischemia reperfusion injuries.

72 resent a major risk factor for hypertension, heart attack, and stroke.

73 sed risk of hypertension, diabetes, obesity, heart attack, and stroke.

74 s may have increased cardiovascular disease, heart attack, and stroke.

75 blood pressure, serum cholesterol, previous heart attack, and treatment for diabetes.

76 For pneumonia, heart attacks, and all-cause mortality, the effect size

77 n many disorders, including ischemic stroke, heart attacks, and reperfusion injury.

78 s for treating damaged heart tissues after a heart attack are normally produced by seeding heart cell

79 s effective at saving lives in patients with heart attacks because it explosively generates plasmin i

80 sociations were limited to smokers who had a heart attack between the ages of 25 and 50 years, with o

81 s such as cardiovascular disease (stroke and heart attack), cancer, chronic respiratory disease, and

82 The 352 women who reported having had a heart attack (cases) were frequency matched 5:1 on age w

83 eir use is associated with increased risk of heart attacks caused by blocking COX-2 in the vasculatur

84 Heart attacks caused by occlusion of coronary arteries a

85 or triaging patients directly to specialized heart-attack centers.

86 etes, and previous admission to hospital for heart attack decreased the relative risk to 1.40 (1.35-1

87 ardiovascular effects and increased risk for heart attacks have been associated with this drug.

88 een periodontal loss of attachment (LOA) and heart attack history for smokers, with odds ratios and 9

89 relationship between periodontal disease and heart attack history.

90 y complications that can lead to strokes and heart attacks if left untreated.

91 , elevated cholesterol level, and history of heart attack in a parent.

92 l damage during surgery, transplantation, or heart attack in humans.

93 h existing estimates of the relative risk of heart attack in individuals attributable to passive smok

94 Self-reported heart attack in the previous 2 years was compared with c

95 rhage in the recreational activity group and heart attack in the VRWii group).

96 ons that eliminate LDLRs raise LDL and cause heart attacks in childhood, whereas mutations that raise

97 rate physical activity reduces mortality and heart attacks in older men with and without diagnosed ca

98 e to the 0% category, the unadjusted odds of heart attack increased with each higher category of atta

99 ction of cardiac biomarkers for diagnosis of heart attack is the key to saving lives.

100 This serum heart attack marker was used as an example of analytes o

101 y and Efficacy Study of MGuard Stent After a Heart Attack [MASTER]; NCT01368471).

102 Although self-reported heart attack may be inaccurate, it indicates increased r

103 ity of life/HRQoL/QoL, myocardial infarction/heart attack/MI and predict*/factor.

104 e and blood pressure surges, that stroke and heart attack most frequently happen.

105 patient are needed to replace losses during heart attack, multiple sclerosis and diabetes.

106 Cardiac immunosensor for early detection of heart attack (myocardial infarction) was developed using

107 Reports of angina, heart attack, myocardial infarction, and arrhythmia attr

108 ve predictive values for reports of paternal heart attack occurring before 55 years of age and for st

109 inite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic str

110 ypertension (for females), diabetes, asthma, heart attack or angina (for females), and stroke (for fe

111 For males, heart attack or angina is higher in the United States on

112 vascular disease was defined as a history of heart attack or heart surgery.

113 vate CHD risk among individuals with a prior heart attack or self-reported pre-existing cardiovascula

114 curs at a mean age of 13 years, usually from heart attack or stroke.

115 aging disease resulting in early death from heart attack or stroke.

116 solve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therap

117 ellular to cellular to whole vessel scale of heart attacks or strokes.

118 hospitalization, bariatric surgery, cancer, heart attack, or stroke.

119 [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart At

120 isodes of care (e.g., treatment of diabetes, heart attack, or urinary tract infection), assigned each

121 gnificantly higher odds of CAD (P </= 0.04), heart attack (P </= 0.01), and congestive heart failure

122 ds of CAD (P </= 0.02), angina (P </= 0.02), heart attack (P </= 0.047), other heart disease (P < 0.0

123 al value of technological change for elderly heart attack patients in 1984-1990.

124 ed to individuals with a self-reported prior heart attack, periodontitis was associated with a 34% de

125 articipants of the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) to establish fea

126 vs placebo in the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART).

127 The Sertraline Antidepressant Heart Attack Randomized Trial assessed HRV from 24-hour

128 katchewan Health database, and the Worcester Heart Attack Registry.

129 although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen

130 option for several diseases such as stroke, heart attack, reperfusion injuries, and rheumatoid arthr

131 stimates of reductions in community rates of heart attacks resulting from smoking restriction laws wi

132 he article "Physical Activity as an Index of Heart Attack Risk in College Alumni", established that m

133 r removal, hospital admission with suspected heart attack, ruptured gut, and ruptured Achilles tendon

134 d pressure correlates with increased risk of heart attack, stroke and progression to heart and kidney

135 tly predicted incident (3 years) thrombosis (heart attack, stroke) risk.

136 e that PAD imposes a high short-term risk of heart attack, stroke, and death.

137 a key role in the pathophysiology of cancer, heart attack, stroke, and other major causes of mortalit

138 ry of coronary artery disease (CAD), angina, heart attack, stroke, and peripheral vascular disease (P

139 ndex, and histories of hypertension, angina, heart attack, stroke, diabetes, rheumatoid arthritis, an

140 ime to the first major cardiovascular event (heart attack, stroke, new or worsening congestive heart

141 ich only a small fraction of lesions lead to heart attack, stroke, or sudden cardiac death.

142 a number of life threatening diseases, e.g., heart attack, stroke, pulmonary embolism.

143 Spikes in deaths due to heart attacks, strokes and other diseases occurred durin

144 clot and, thus, have a critical influence on heart attacks, strokes, and embolisms.

145 e the risk of cardiovascular disease events (heart attacks, strokes, and the need for arterial revasc

146 nzymes so as not to form a thrombus, causing heart attacks, strokes, or pulmonary emboli, but the ori

147 As part of the Worcester Heart Attack Study, a community-wide study examining cha

148 Building on the Worcester Heart Attack Study, an ongoing community-wide investigat

149 The Morgan Incongruence of Heart Attack Symptoms Index was used to quantify symptom

150 fied by smoking status and tertile of age at heart attack, the statistically significant associations

151 abetes, congestive heart failure, or a prior heart attack, the utilization patterns closely followed

152 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) have generated worldwide rea

153 sive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) have shown the risk of CHF t

154 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is re-evaluated considering

155 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that the primary end

156 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the

157 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 42 418 high-risk hypertensi

158 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind,

159 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), but it is unknown whether t

160 sive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT), low-dose chlorthalidone as

161 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT; pravastatin 40 mg versus

162 The Sertraline Antidepressant Heart Attack Trial (SADHART) tested the safety and effic

163 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]; NCT00000542).

164 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial and the Anglo-Scandinavian Cardiac Ou

165 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial failed to achieve similar success due

166 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial failed to find a significant reductio

167 sive and Lipid-Lowering treatment to prevent Heart Attack Trial reported that treatment initiated wit

168 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) determined that treatment with amlod

169 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) with baseline diabetes, incident dia

170 sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), a randomized, double-blind, active-

171 Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

172 Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

173 Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

174 rt Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

175 Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

176 Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

177 Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

178 Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

179 Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

180 Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a B

181 e periodontal assessments and information on heart attack were evaluated.

182 The outcome was the self-reported history of heart attack (yes vs. no).